Recent genetic and genomics approaches have yielded novel insights in the pathogenesis of Systemic Lupus Erythematosus (SLE) but the diagnosis, monitoring and treatment still remain largely empirical 1,2 . We reasoned that molecular characterization of SLE by whole blood transcriptomics may facilitate early diagnosis and personalized therapy. To this end, we analyzed genotypes and RNA-seq in 142 patients and 58 matched healthy individuals to define the global transcriptional signature of SLE. By controlling for the estimated proportions of circulating immune cell types, we show that the Interferon (IFN) and p53 pathways are robustly expressed. We also report cell-specific, diseasedependent regulation of gene expression and define a core/susceptibility and a flare/activity disease expression signature, with oxidative phosphorylation, ribosome regulation and cell cycle pathways being enriched in lupus flares. Using these data, we define a novel index of disease activity/severity by combining the validated Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 1 with a new variable derived from principal component analysis (PCA) of RNA-seq data. We also delineate unique signatures across disease endo-phenotypes whereby active nephritis exhibits the most extensive changes in transcriptome, including prominent drugable signatures such as granulocyte and plasmablast/plasma cell activation. The substantial differences in gene expression between SLE and healthy individuals enables the classification of disease versus healthy status with median sensitivity and specificity of 83% and 100%, respectively. We explored the genetic regulation of blood transcriptome in SLE and found 3142 cis-expression quantitative trait loci (eQTLs). By integration of SLE genome-wide association study (GWAS) signals and eQTLs from 44 tissues from the GenotypeTissue Expression (GTEx) consortium, we demonstrate that the genetic causality of SLE arises from multiple tissues with the top causal tissue being the liver, followed by brain basal ganglia, adrenal gland and whole blood. Collectively, our study defines distinct susceptibility and activity/severity signatures in SLE that may facilitate diagnosis, monitoring, and personalized therapy.
Systemic Lupus Erythematosus (SLE) is the prototypic systemic autoimmune disease that manifests a wide range of clinical and molecular abnormalities 2, 3 . Despite advances in the pathogenesis and treatment, several unmet needs exist. To cite a few, the molecular events explaining the variability of SLE and the interspersing periods of inactivity and activity remain unspecified. The disease is often challenging to diagnose, especially at early stages, and there is lack of robust diagnostic criteria 4 .
Existing instruments to monitor SLE suffer from inherent limitations and there are no accurate biomarkers of disease activity and severity. Moreover, the extent to which clinically-defined therapeutic targets correlate with changes in transcriptome is not known. Notwithstanding the successful introduction of the first targeted biological agent in SLE 5 , a considerable proportion of patients will be unresponsive to existing treatments, highlighting the need for novel, targeted therapies based on the underlying immune aberrancies. To examine these, we performed transcriptome profiling by RNA-seq (Supplementary Figure 1) 7 . A broad view of the biological regulation of SLE is provided by a network enrichment map of significantly enriched GO terms derived from DEGs (Supplementary Figure 2E) . These results reveal marked aberrancies and specific signatures in SLE whole blood transcriptome.
Whole blood assays, while relevant to define complex inflammatory signatures 8, 9 , do not inform on cell-specific mechanisms. To address this, we estimated the proportions of different immune cell types for each individual by using blood transcriptome deconvolution implemented in CIBERSORT 10 .
We report significant differences in blood cell composition including reduction of naïve B-cells 11 and natural killer cells 12, 13 , and increase of memory activated CD4 + T-cells 14 and myeloid-linage cells [15] [16] [17] [18] in SLE versus healthy individuals ( Figure 1A) . Next, we defined a global gene expression signature independent of the differences in cell composition by controlling for the estimated proportions of cell types, and found 1613 DEGs (5% FDR) between SLE and healthy individuals, which represents a 76% decrease in DEGs from the previous analysis. Pathway and GO term enrichment analysis revealed that the IFN signature ( Figure 1B-C) is independent of cell type composition. By interrogating the interferome database 19 , we found that the DEGs are indicative of both type I and type II IFN response, while they also showed enrichment in the p53 signaling pathway (Figure 1B) , which is implicated in apoptotic cell clearance and maintenance of immune tolerance 20, 21 . These data demonstrate a robust transcriptional signal -independent of blood cell type composition -that could facilitate the discovery of novel biomarkers.
To unravel cell-specific gene perturbations, we examined whether cell type composition has a different effect on gene expression between the SLE and healthy state. We controlled for the estimated proportions of all other immune cell types and tested for the significance of the disease Í estimated cell proportion interaction term. We quantified the proportion of true positives estimated from the enrichment of significant p-values (π1) 22 ( Figure 1D ). For naive and memory B-cells, CD4+ memory resting T-cells, CD8+ T cells, and neutrophils, the corresponding π1 values were above zero, suggesting that varying proportion of these cells interacts with the effects that cell type proportions have on gene expression in SLE versus healthy individuals. Illustratively, increasing proportion of neutrophils correlated positively with GTPBP2 (GTP Binding Protein 2) in SLE but not in healthy individuals ( Figure 1E ). The same trend was observed for the correlation between CD4+ memory resting T-cells and CD1c (cluster differentiation 1c) ( Figure 1F ). GTPBP2 interacts with IRF5 to regulate type I IFN production 23 , while CD1c is a cell membrane glycoprotein 24 that mediates the presentation of modified peptides to CD1c-restricted T cells 25 and has been linked to autoimmunity 26, 27 . Together, differences in whole blood transcriptome in SLE are driven by both altered abundances of circulating immune cell types and cell-specific regulation of gene expression depending on disease status.
Remission of disease activity has been introduced as therapeutic target in SLE 28 Figure 3) suggesting persistence of immune system activation and inflammation despite remission of clinical signs and symptoms. By comparing patients with clinically inactive SLE but evidence for serologic activity (high anti-dsDNA titers, low serum complement) 29 against those who are both clinically and serologically inactive, we found no DEGs at 5% FDR, corroborating studies showing similar favorable prognosis for these two groups 30 .
Flares of disease activity are frequent in SLE and contribute to accrual of irreversible organ damage 31 .
Defining the signature of increased SLE activity has pathogenic and clinical ramifications. To this end, we selected the DEGs from the comparison of inactive versus active SLE that are not included in the 'core' disease signature. A total 365 DEGs were identified, which were enriched for KEGG pathways such as oxidative phosphorylation, consistent with the described alterations in mitochondrial mass and membrane potential in lupus T cells [32] [33] [34] and the enhanced oxidative stress [35] [36] [37] . Other enriched pathways included ribosomes and cell cycle. Thus, increases in SLE activity may be linked to perturbed expression of genes that regulate metabolism, protein synthesis and proliferation of peripheral blood immune cells. The flare gene signature could enable the earlier identification of an impending clinical flare and more effective use of pre-emptive treatment, an unmet need in SLE in view of the limitations of traditional serologic tests 38, 39 .
Biomarkers that accurately reflect disease severity and the underlying molecular pathogenesis, represent an additional unmet need in SLE. We assessed transcriptome differences according to varying degrees of disease activity/severity by using the validated SLEDAI-2K index as a quantitative measure (0=inactive; 1-5=mild; 6-10=moderate; >10=severe disease) 40 , among patients and healthy individuals (fixed score of -1). We performed PCA ( Figure 3A) on the identified 3690 DEGs (5% FDR) (Supplementary Table 6 ) and defined PC1 (explaining 23% of the variance) as a new variable summarizing the expression properties of genes that recapitulate SLE severity ( Figure 3B) . Notably, PC1 clusters closely patients with inactive and low disease activity, which is consistent with evidence that both these states have a favorable outcome 41, 42 . Pathway analysis showed enrichment in the oxidative phosphorylation and cell cycle KEGG pathways, similar to the 'flare' signature, suggesting that these two biological processes may be implicated not only in disease activity but also in severity. Functionally grouped networks of GO terms revealed gene signatures related to protein ubiquitination, electron transport chain, protein phosphorylation, cell cycle, defense response and regulation of response to stress ( Figure 3C ), all of which have been linked to SLE 37, 43, 44 . These results point out the involvement of multiple molecular pathways and biological processes in determining SLE progression/severity and suggest that whole blood transcriptome may serve as a robust biomarker of SLE activity and severity.
SLE can affect multiple organs but the molecular basis of this heterogeneity remains elusive. Accordingly, SLE patients were grouped according to predominant organ activity ( Table 1) and multiple comparisons were carried out. By comparing patients with active renal disease (nephritis) (group 1) versus those with activity from other organs (combined groups 2,3,4), we found 136 DEGs (5% FDR). These genes were enriched in functionally grouped networks of granulocyte activation and antimicrobial humoral response (Supplementary Figure 4) , consistent with the role of neutrophil activation 45, 46 and their death by formation of chromatin extracellular traps, [47] [48] [49] and of plasmablasts/plasma-cells 11,50-52 in lupus nephritis. To further discern the transcriptome basis for kidney involvement in SLE, we took the intersection of DEGs in active nephritis (group 1) versus inactive SLE (combined groups 5 and 6) (1375 DEGs, 5% FDR) with those in active versus inactive SLE (377 DEGs). A total 305 genes were common in the two comparisons, suggesting a step-wise progression of transcriptome alterations from inactive to active non-renal and active renal SLE status. By comparing patients with active versus inactive nephritis, we found global gene expression differences captured by PCA (Supplementary Figure 5) , while differential gene expression analysis between these two groups revealed 1496 DEGs. Together, lupus nephritis displays marked and gradually enriched changes in whole blood gene expression compared to other SLE subsets, some of which may be drugable.
SLE exhibits a striking gender bias with females being affected 7 to 12 times more frequently than men, yet the latter suffering from more severe disease 53 . To gain insights into the molecular basis of this sexual dimorphism, we took the non-overlapping sets of DEGs in male versus female SLE (Bonferroni significant) and male versus female healthy (90% FDR) individuals. Six genes showed gender-biased expression in SLE (Supplementary Figure 6A) , two of which (SMC1A, ARSD) are located on X chromosome and escape X-inactivation. SMC1A, encoding for the cohesin complex protein Structural Maintenance Of Chromosomes 1A [54] [55] [56] , demonstrated the strongest gender bias (Supplementary Figure 6A- Figure  6C) . Although preliminary, these results provide candidate genes for further studies on the sexual dimorphism in the disease.
B), and this was confirmed in purified CD4+ T-cells (Supplementary
SLE diagnosis can be challenging especially at early stages before an adequate number of features accumulate 4 . We asked whether we could accurately classify individuals based on their transcriptional profile by building multiple classifiers based on Linear Discriminant Analysis (LDA) by the use of DEGs as features (see Methods). We measured a median diagnostic accuracy of 90% in the validation set with 86% sensitivity and 100% specificity (Supplementary Figure 7) . Patients who were most frequently misclassified as healthy individuals had lower frequency of renal involvement, ANA/anti-dsDNA autoantibodies, and were less frequently treated with immunosuppressive agents, suggesting an overrepresentation of milder disease. Thus, whole blood transcriptome might be used to assist the diagnosis of SLE, a finding that needs to be confirmed and validated in longitudinal studies of patients with both early and established disease.
Definition of regulatory genetic effects is crucial to our understanding of the molecular basis of complex diseases 57 . We explored the genetic regulation of blood transcriptome in SLE by assessing expression-Quantitative Trait Loci (eQTLs) in our cohort. We found 3142 cis-eQTLs (5% FDR), with highly significant cis-eQTLs clustering close to the transcription start site of the genes (Supplementary Figure 8A-B) . These eQTLs replicated well (pi=0.89, Supplementary Figure 8C ) with a blood RNA-seq study in healthy donors 58 , suggesting the lack of disease specificity. This could be due to lack of adequate power to detect such effects and/or the need to study specific immune cell types. Assessing eQTLs from multiple tissues could enhance our interpretation of GWAS signals, as most of them reside in non-coding genome areas 59 and enable the identification of the causal genes and tissues. To estimate the tissue(s) that determine the genetic causality of SLE, we employed the Regulatory Trait Concordance (RTC) method 57, 60 that estimates the causal tissues by using eQTLs in 44 tissues from the GTEx consortium 61 ( Figure 4) . We found that the top causal tissue is liver followed by brain basal ganglia, adrenal gland and whole blood, suggesting that the genetic causality of SLE arises from multiple tissues. The finding of liver being linked as the top causal tissue is in agreement with our result that SLE exacerbation is associated with changes in expression of genes that regulate metabolism 62 .
In summary, SLE is an autoimmune disease with marked clinical and immunological heterogeneity, waxing and waning course, and variable response to immunosuppressive and biological treatments. In a previous study, Banchereau et al 63 profiled the blood transcriptome by microarrays in a longitudinal cohort of pediatric patients. However, their analysis focused on detection of immune correlates of disease activity and treatment effects based on a priori defined modules of transcripts co-expressed in blood across various immunological conditions. Our RNA-seq analysis in a wellcharacterized cohort of adult SLE patients provides an unbiased characterization of whole-blood gene signatures associated not only with susceptibility but also, with clinically relevant disease progression such as increased activity and major organ involvement. We also defined cell-specific effects of the disease on gene expression, which may provide insights into the pathogenic role of specific immune cell types by the further studies in purified cells. DEGs are involved in biological networks and pathways that are pertinent to SLE pathogenesis and may represent putative therapeutic targets. Importantly, we show that whole blood transcriptome can classify SLE versus healthy individuals with excellent specificity putting forward the possibility of using blood gene profiling as a diagnostic tool. Finally, our studies on the genetic variation on gene expression suggest that in addition to whole blood, other tissues such as the liver may determine genetic causality in SLE. FP7-REGPOT-2011-1).
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Methods

Patients
Study design
We performed RNA-seq to measure gene expression in whole blood from SLE patients and matched for age and sex healthy individuals. After quality control (Supplementary Figure 1) , we obtained gene quantifications for 142 SLE patients and 58 healthy volunteers, measuring the expression of ~21.000 genes. All individuals were genotyped and imputed towards the 1000 genomes phase III reference panel 65, 66 , yielding a set of ~6.9 millions of variants. For all SLE individuals we collected a variety of clinical phenotypes such as the 1997 American College of Rheumatology revised criteria for classification of SLE, presence of serum autoantibodies, physician-rated disease activity (PGA), an index measuring the activity of the disease (SLEDAI-2K) 1,67 , and the medical treatment at the time of sample collection.
Genotyping
All the individuals were genotyped with the Illumina HumanCoreExome-24 array. The individuals were phased with SHAPEIT 68 and imputed to the 1000 Genomes Project Phase III 66 using IMPUTE2 69 .
After imputation, we filtered out SNPs with MAF <=0.05, IMPUTE score < 0.4 and Hardy-Weinberg equilibrium p-value <5e-7. After filtering we ended up with ~7M variants for association testing.
RNA sequencing, mapping and quantifications
RNA libraries were prepared with the Illumina TruSeq sample preparation kit and were sequenced on Illumina HiSeq2000 according the manufacturer's instructions. 49 bp paired-end reads were mapped to the GRCh37 reference human genome using the GEM mapper 70 . We kept reads with mapping quality >150 to quantify exons and genes corresponding to reads that are uniquely mapped to the genome, with the correct orientation between pairs, allowing for 5 mismatches for both reads of a pair. Exon quantification was performed using the GENCODE annotation v15 71 . The overlapping exons of a gene were merged into a meta-exon unit with starting coordinates the start position of the first exon that is merged and end position the end position of the last exon that is merged. We counted reads as mapped to this meta-exon unit if there was an overlap between either the start or end position of the read with the meta-exon. Gene level quantifications were then obtained by summing the meta-exons counts for each gene.
Quality control of RNA sequencing data
Several metrics were used to assess the quality of the RNA-seq data (Supplementary Figure 1A) . We measured the proportion of exonic/total reads in quantified exons per sample. Samples with a ratio less than 0.2 were excluded from further analysis as technical outliers. We further excluded samples being outliers in the PCA plot (Supplementary Figure 1B) . These samples were also outliers based on the proportion of total reads mapped to hemoglobin genes (Supplementary Figure 1C) . Two samples were also excluded from further analysis based on discrepancy of the sex identified by the RNA-seq data and our clinical records (Supplementary Figure 1D) . Finally, MBV 72 was used to correct for any sample label swaps or cross contamination for the RNA-seq and the genotyped data without identifying any swaps in our dataset.
Differential gene expression analysis
We included 21851 genes in the analysis and used this set of genes in all downstream analyses for consistency. A gene was included if it had at least 5 reads in 10% of either the SLE or the healthy individuals. DESeq2 73 was used to call differentially expressed genes by including GC content, RNA integrity (RIN), center of collection, insert size mode, age, gender, amount of RNA to construct the library and plate number as technical covariates. These covariates were found to influence gene expression by performing step wise regression between gene expression and all the technical covariates that were obtained from the experimental procedure. Benjamini-Hochberg was used to assess significance at 5% or 1% false discovery rate (FDR). To identify genes that were differentially expressed despite the immune cell composition we used the same covariates as before by including the estimated cell proportions as covariates in the model. To assess cell specific differentially expression we used the latter model by including a disease Î estimated proportion status interaction term and obtained p-values for every gene for the interaction term. For this analysis, we estimated the proportion of true positives from the enrichment of significant p-values by using the π1 statistics. To specify the DEGs based on disease severity/activity the SLEDAI-2K index was used as a quantitative measurement by fixing the score to -1 for healthy individuals. To call up and down regulated DEGs we used Spearman rank correlation between gene expression and the SLEDAI index.
Pathway and GO term enrichment analysis
To functionally characterize the identified DEGs a comprehensive functional enrichment gene set analysis for KEGG pathways and GO terms was performed by using the ClueGO 74 plugin of Cytoscape 75 . Briefly, ClueGO visualize the functionally grouped networks of enriched pathways and GO terms. The enrichment is based on a two-sided hypergeometric test and corrected for multiple testing with either Benjamini-Hochberg for KEGG pathways or Bonferroni for GO terms by setting the threshold of the adjusted p-values in each case at 0.05.
We used a more stringent approach with GO terms by Bonferroni correction and fusion criteria implemented in the ClueGO plugin to reduce the plethora of the terms that have the same enriched genes allowing only for the most representative "parent" or "child" terms in the networks. Each node represents a pathway or a GO term and the size of each node represents the enrichment significance.
The connection between nodes is based on Cohen's kappa statistic score (≥ 0.4) which depends on the gene sharing between nodes. For each network, only the most significant node is labeled.
Cell type estimation
We used CIBERSORT 10 to estimate the proportion of different immune cell types in whole blood in our dataset. CIBERSORT uses a well-defined gene expression signature (LM22) that consists of 547 genes that precisely differentiate mature human hematopoietic cells. To perform the analysis, we used the LM22 gene matrix as reference and normalized values for the library size per sample in our dataset obtained from the estimateSizeFactors function in DESeq2.
CD4+ T-cell purification and RT-PCR
Peripheral blood mononuclear cells (PBMCs) from SLE patients and age-matched healthy blood volunteers were isolated by Ficoll-Histopaque (Sigma-Aldrich) density-gradient centrifugation of heparinized venous blood. CD4+ T lymphocytes (98% purity) were isolated by negative immunomagnetic selection (Miltenyi Biotec, Bergisch Gladbach, Germany). Total RNA was extracted using the TRIzol™ extraction method and the Turbo DNAse kit (Ambion) was used to eliminate genomic DNA contamination. cDNA was prepared using Perfect Real time cDNA Synthesis Kit (Takara) according to manufacturer's protocol. 200ng of RNA were used as a template for every reaction. RNAse H (2U/reaction) was added to clean the resulting cDNA from any RNA and incomplete cDNA products. PCR amplification of the resulting cDNA samples was performed using appropriate volumes of KAPA SYBR® FAST Universal 2x qPCR Master Mix and specific for each gene primers at a CFX Connect™, Real-Time System. Total volume of each PCR reaction was 20μl. Expression was normalized to GAPDH and calculated by the change-in-threshold method [2^(-ΔΔCT)]. The following primer sets were used: (5'à3'): SMC1A forward human: CAT CAA AGC TCG TAA CTT CCT CG; SMC1A reverse human: CCC CAG AAC GAC TAA TCT CTT CA; GAPDH forward human: CAT GTT CCA ATA TGA TTC CAC C; GAPDH reverse human: GAT GGG ATT TCC ATT GAT GAC.
Classification we performed Linear Discriminant Analysis (LDA) by using DEGs as features. We divided our dataset to training (90%, corresponding to 128 SLE patients and 52 healthy individuals) and validation set (10%, corresponding to 14 SLE patients and 6 healthy individuals) and run 1000 iterations. For each iteration, we performed differential gene expression analysis between SLE and healthy using the training set and built the LDA classifier based on the identified DEGs in order to measure the accuracy, sensitivity (the probability of calling an SLE individual as patient) and specificity (the probability of calling a healthy individual as healthy) of the classifier. We found a median of 6126 DEGs ranging from 4671 to 7222 DEGs. We chose the strategy of building multiple classifiers to account for the SLE heterogeneity by inserting perturbations in the models by sampling in each iteration different individuals. In doing so, we achieved high levels of accurate classification.
eQTL mapping eQTL analysis was performed in a 1MB window upstream or downstream the transcription start site of the gene using QTLtools 76 . We scaled the total number of raw reads per sample to the median number of all samples. We removed genes that were not expressed in 90% of the individuals and then we applied PCA to account for hidden technical variation. Significance was assessed by using the qvalue R package 22 on beta approximated empirical p-values from 1000 permutations.
Replication was assessed by using the π1 statistic on the p-value distribution obtained from significant cis-eQTLs.
Regulatory Trait Concordance (RTC)
We have previously described RTC score to assess whether a GWAS variant and an eQTL are tagging the same causal variant 57 . Briefly, we expect that if a GWAS variant and an eQTL do tag the same causal variant, by removing the genetic effect of the GWAS variant will have a significant consequence on the eQTL association. Following up, we can now estimate the causal tissues for complex traits and diseases by measuring the tissue sharing probabilities of eQTLs and calculating probabilities that a GWAS variant and the eQTL do tag the same functional effect. By normalizing the GWAS-eQTL probabilities with the tissue sharing estimates of the eQTLs, we can estimate the tissues from which GWAS genetic causality arises 60 . KEGG pathways, that were regulated by genes belonging to the "flare" gene signature is also enriched suggesting that these genes not only capture the inactive to active progression but also the different levels of severity. Functionally grouped networks of GO terms on the right. Multiple biological aberrations are captured by differences in gene expression based on different levels of SLE activity. 
